A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo

Journal of Pharmacology and Experimental Therapeutics

Volumn 316, Issue 2, 2006, Pages 780-788

  Lunn, Charles A ^a   Fine, Jay S ^a   Rojas Triana, Alberto ^a   Jackson, James V ^a   Fan, Xuedong ^a   Kung, Ted T ^a   Gonsiorek, Waldemar ^a   Schwarz, Martin A ^a   Lavey, Brian ^a   Kozlowski, Joseph A ^a   Narula, Satwant K ^a   Lundell, Daniel J ^a   Hipkin, R William ^a   Bober, Loretta A ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANTIGEN; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR CB2 AGONIST; CHEMOKINE; CYCLIC AMP; DEXANABINOL; FORSKOLIN; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); N [[4 [[4 METHOXY 2 [[(4 METHOXYPHENYL)SULFONYL]SULFONYL]PHENYL]SULFONYL] PHENYL]ETHYL]METHANESULFONAMIDE; OVALBUMIN; PHOSPHORUS DERIVATIVE; PYRAZOLE DERIVATIVE; SCH 336; UNCLASSIFIED DRUG;

ACUTE DISEASE; ALLERGIC ASTHMA; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL LEVEL; CHRONIC DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; EOSINOPHILIA; FEMALE; IN VIVO STUDY; INFLAMMATORY DISEASE; LEUKOCYTE MIGRATION INHIBITION; MALE; MEMBRANE BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BORNANES; CANNABINOIDS; CELL MEMBRANE; CHEMOTAXIS, LEUKOCYTE; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; FEMALE; GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE); HUMANS; HYPERSENSITIVITY, DELAYED; LEUKOCYTES, MONONUCLEAR; MICE; MICE, INBRED STRAINS; PROTEIN BINDING; PULMONARY EOSINOPHILIA; PYRAZOLES; RECEPTOR, CANNABINOID, CB2;

EID: 31144468211     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.093500     Document Type: Article

References (40)

1. 2: implication for intracellular signalization cross-regulation. Mol Pharmacol 55:473-480.
2. Buckley NE, McCoy KL, Mezey E, Bonner T, Zimmer A, Felder CC, Glass M, and Zimmer A (2000) Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur J Pharmacol 396:141-149.
3. 2 peripheral cannabinoid receptors during B-cell differentiation. Blood 92:3605-3615.
4. Charo IF and Taubman MB (2004) Chemokines in the pathogenesis of vascular disease. Circ Res 95:858-866.
5. Chen L, Pei G, and Zhang W (2004) An overall picture of chemokine receptors: basic research and drug development. Curr Pharm Des 10:1045-1055.
6. Cohn L, Elias JA, and Chupp GL (2004) Asthma: mechanisms of disease persistence and progression. Annu Rev Immunol 22:789-815.
7. De Clercq E (2003) The bicyclam AMD3100 story. Nat Rev Drug Discov 2:581-587.
8. de Ligt RA, Kourounakis AP, and IJzerman AP (2000) Inverse agonism at G protein-coupled receptors: (patho)physiological relevance and implications for drug discovery. Br J Pharmacol 130:1-12.
9. Fine JS, Jackson JV, Rojas-Triana A, and Bober LA (2000) Evaluation of chemokine- and phlogiston-mediated leukocyte chemotaxis using an in vivo sponge model. Inflammation 24:331-346.
10. Fine JS, Rojas-Triana A, Jackson JV, Engstrom LW, Deno GS, Lundell DJ, and Bober LA (2003) Impairment of leukocyte trafficking in a murine pleuritis model by IL-4 and IL-10. Inflammation 27:161-174.
11. Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnálek P, ZádorováZ, Palmer T, and Donoghue S, for the Natalizumab Pan-European Study Group (2003) Natalizumab for active Crohn's disease. N Engl J Med 348:24-32.
12. Gonzalo JA, Lloyd CM, Kremer L, Finger E, Martinez-A C, Siegelman MH, Cybulsky M, and Gutierrez-Ramos JC (1996) Eosinophil recruitment to the lung in a murine model of allergic inflammation: the role of T cells, chemokines and adhesion receptors. J Clin Investig 98:2332-2345.
13. Horuk R (2003) Development and evaluation of pharmacological agents targeting chemokine receptors. Methods 29:369-375.
14. 2 receptor. Curr Pharm Des 6:1323-1337.
15. Jorda MA, Verbakel SE, Valk PJ, Vankan-Berkhoudt YV, Maccarrone M, Finazzi-Agro A, Lowenberg B, and Delwel R (2002) Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. Blood 99:2786-2793.
16. Kaplan BL, Rockwell CE, and Kaminski NE (2003) Evidence for cannabinoid receptor-dependent and -independent mechanisms of action in leukocytes. J Pharmacol Exp Ther 306:1077-1085.
17. Kasserra CE, Harris P, Stenton GR, Abraham W, and Langlands JM (2004) IPL576,092, a novel anti-inflammatory compound, inhibits leukocyte infiltration and changes in lung function in response to allergen challenge. Pulm Pharmacol Ther 17:309-318.
18. 2 receptor-dependent mechanism. J Biol Chem 278:24469-24475.
19. Kung TT, Jones H, Adams GK 3rd, Umland SP, Kreutner W, Egan RW, Chapman RW, and Watnick AS (1994) Characterization of a murine model of allergic pulmonary inflammation. Int Arch Allergy Immunol 105:83-90.
20. Lavey BJ, Kozlowski JA, Hipkin RW, Gonsiorek W, Lundell DJ, Piwinski JJ, Narula S, and Lunn CA (2005) Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial SAR studies. Bioorg Med Chem Lett 15:783-786.
21. Mahad DJ and Ransohoff RM (2003) The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin Immunol 15:23-32.
22. 2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol 3:62-67.
23. 2 receptor participation. J Pharmacol Exp Ther 289:1620-1625.
24. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GPA, Libonati MA, Willmer-Hulme AJ, Dalton CM, Miszkiel KA, and O'Connor PW; the International Natalizumab Multiple Sclerosis Trial Group (2003) A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 348:15-23.
25. Munro S, Thomas KL, and Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature (Lond) 365:61-65.
26. Munitz A and Levi-Schaffer F (2004) Eosinophils: "new" roles for "old" cells. Allergy 59:268-275.
27. Oka S, Ikeda S, Kishimoto S, Gokoh M, Yanagimoto S, Waku K, and Sugiura T (2004) 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces the migration of EoL-1 human eosinophilic leukemia cells and human peripheral blood eosinophils. J Leukoc Biol 76:1002-1009.
28. 2 receptor and its endogenous ligand 2-arachidonoylglycerol in 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation in mouse ear. J Biol Chem 280:18488-18497.
29. Owen C (2001) Chemokine receptors in airway disease: which receptors to target? Pulm Pharmacol Ther 14:193-202.
30. Paoletti S, Petkovic V, Sebastiani S, Danelon MG, Uguccioni M, and Gerber BO (2005) A rich chemokine environment strongly enhances leukocyte migration and activities. Blood 105:3405-3412.
31. Quinones MP, Estrada CA, Kalkonde Y, Ahuja SK, Kuziel WA, Mack M, and Ahuja SS (2005) The complex role of the chemokine receptor CCR2 in collagen-induced arthritis: implications for therapeutic targeting of CCR2 in rheumatoid arthritis. J Mol Med 83:672-681.
32. 2 cannabinoid receptor. J Pharmacol Exp Ther 284:644-650.
33. 2 receptors. J Neuroimmunol 109:155-163.
34. Shire D, Calandra B, Bouaboula M, Barth F, Rinaldi-Carmona M, Casellas P, and Ferrara P (1999) Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. Life Sci 65:627-635.
35. Sircar I, Gudmundsson KS, Martin R, Liang J, Nomura S, Jayakumar H, Teegarden BR, Nowlin DM, Cardarelli PM, Mah JR, et al. (2002) Synthesis and SAR of N-benzoyl-L-biphenylalanine derivatives: discovery of TR-14035, a dual α4β7/α4β1 integrin antagonist. Bioorg Med Chem 10:2051-2066.
36. Steele AD, Szabo I, Bednar F, and Rogers TJ (2002) Interactions between opioid and chemokine receptors: heterologous desensitization. Cytokine Growth Factor Rev 13:209-222.
37. Varnes JG, Gardner DS, Santella JB 3rd, Duncia JV, Estrella M, Watson PS, Clark CM, Ko SS, Welch P, Covington M, et al. (2004) Discovery of N-propylurea 3-benzylpiperidines as selective CC chemokine receptor-3 (CCR3) antagonists. Bioorg Med Chem Lett 14:1645-1649.
38. Widdowson KL, Elliott JD, Veber DF, Nie H, Rutledge MC, McCleland BW, Xiang JN, Jurewicz AJ, Hertzberg RP, Foley JJ, et al. (2004) Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor. J Med Chem 47:1319-1321.
39. 2+-independent protein kinase Cs mediate heterologous desensitization of leukocyte chemokine receptors by opioid receptors. J Biol Chem 278:12729-12736.
40. 2 receptor-mediated, cytokine-dependent pathway. J Immunol 165:373-380.